{
  "id": 5384758,
  "title": "FDA Approves Breakthrough Drug Rasonque for Metastatic Pancreatic Cancer",
  "url": "https://urgent.news/2026/09/03/fda-approves-breakthrough-drug-rasonque-for-metastatic-pancreatic",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T16:38:29.000Z",
  "source": {
    "name": "Healthline News",
    "slug": "healthline-news",
    "url": "https://www.healthline.com/health-news/fda-approves-rasonque-metastatic-pancreatic-cancer"
  },
  "original_language": "en",
  "account": "The FDA has approved Rasonque, a new drug designed to fight metastatic pancreatic cancer, the sixth-leading cause of cancer-related deaths worldwide. In a clinical trial, patients receiving Rasonque experienced a significantly longer average survival of 13.2 months, compared to 6.7 months for those treated with chemotherapy alone. Rasonque targets a specific protein called RAS, which is responsible for driving the growth and spread of pancreatic cancer cells. Unlike traditional chemotherapy, Rasonque is a once-daily oral pill that works to neutralize the cancer-driving signals, ultimately causing the cancer cells to die. Experts are optimistic about the drug's potential, as it represents a significant advancement in the treatment of a deadly form of cancer.",
  "summary": "The FDA approved Rasonque (daraxonrasib), a groundbreaking new drug to treat metastatic pancreatic cancer. Photo courtesy of Revolution Medicines The FDA approved Rasonque, a new drug to treat the most common type of pancreatic cancer. A clinical trial found that those who received Rasonque had more than double the average survival rate: around 13 months compared to just over 6 months with…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}